Latest News

Despite often being highly treatable, nonmelanoma skin cancers account for millions of biopsies, procedures, and follow-up visits annually, creating a substantial healthcare burden.

Do nighttime collagen masks actually work or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

The FDA has accepted Replimune's third resubmitted BLA for RP1 plus nivolumab in advanced melanoma, setting an August 2 PDUFA date.

An Evolving Paradigms event led by Darrell S. Rigel, MD, MS, compared PD-1/PD-L1 immunotherapies for advanced cutaneous squamous cell carcinoma, with referral guidance and toxicity alerts.

Lim considers mentoring and helping develop the next generation of dermatologists one of his most meaningful contributions to the specialty.

Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of June.

Kymera Therapeutics finished enrollment in its phase 2b BROADEN2 trial of KT-621 nearly six months early, moving up topline AD data to year-end 2026.

Andrew Krakowski, MD, encourages involving both caregivers and children in treatment decisions, giving young patients a sense of ownership that can significantly improve adherence.

State melanoma reporting data reveals a striking gap between one Arizon dermatologist's detection rates and his peers, and a possible explanation rooted in how dermoscopy is taught.

This review of the latest dermatological studies includes insights into vitiligo, including emerging surgical techniques, the impact of social media, camouflage agents, and more.

An international survey shows vitiligo drives stigma, sun avoidance, and daily limits, urging better treatment guidance and mental health support.

Lisa Pruett, MD, FAAD, shares evidence-based acne care, debunks summer retinoid myths, and explains how Glo2Facial oxygenation and exfoliation support clearer skin and fade marks.

As payers escalate automated denial programs targeting dermatology's E/M claims, the data shows practices that appeal consistently win, yet fewer than 1% ever do.